Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can gentle sensory therapy soothe severe schizophrenia?

NCT ID NCT07769749

Symptom relief Sponsor: The Jerzy Kukuczka Academy of Physical Education in Katowice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This trial asks whether basal stimulation therapy—a gentle approach using touch and sensory cues—can improve the health and well-being of adults with schizophrenia who live in permanent institutional care. Participants, aged 55 and older with long-standing schizophrenia, will receive either standard physiotherapy alone or physiotherapy plus basal stimulation twice a week for six weeks. Researchers will measure changes in consciousness, cognitive function, and blood markers to see if this therapy offers added benefits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
basal stimulation therapy (a gentle sensory-based therapy) combined with standard physiotherapy
What this could lead to
If effective, this therapy could offer a drug-free way to ease anxiety and improve quality of life for people with severe schizophrenia in long-term care.
What could go wrong
This is a very small early-stage study (12 participants), so results may not apply broadly. The therapy is gentle, but its benefits remain unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 12 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Study inclusion criteria: * women and men aged ≥ 55 years, * consent of the legal guardian/caregiver to participate in the study, * schizophrenia clinically confirmed for at least 5 years, with predominance of negative symptoms, * stable drug therapy (treatment unchanged for at least 3 months) * functional ability of everyday life on the Barthel scale below 40 points. The exclusion criteria from the study will be: * lack of consent to participate in the study; * pregnancy * general contraindications (acute inflammatory conditions and diseases accompanied by fever, venous thrombosis, unstable arterial hypertension , early condition after contrast-enhanced computed tomography, early condition after lumbar puncture, general serious condition of the patient ) * exacerbation of the main disease (acute psychosis, severe anxiety, tendency to active aggression, visual seizures) * active cancer; * diseases of the nervous system (neuropathies, stroke , damage to the cerebellum, labyrinth) causing altered sensitivity to stimuli; * diseases and illnesses of the musculoskeletal system that significantly disturb the body's balance and the mobility of the limbs; * pressure ulcers grade IV and V on the Torrance scale.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizophrenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

schizophrenia schizophrenia 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Schizophrenia 1 (disorder)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinical Psychiatric Hospital SPZOZ in Rybnik, Poland

    Rybnik, Silesian Voivodeship, 44-200, Poland

  • Jerzy Kukuczka Academy of Physical Education in Katowice, Poland

    Katowice, Silesian Voivodeship, 40-065, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.